Assignee
SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD
CN·1 granted patent·6 pending applications·2 citations·filing 2019–2022
Top patents by PatentIndex Score
7 records- 0176US11845962B2Method for large-scale production of lentivirus by using GMP-level serum-free suspension cellsSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2019·Granted Dec 19, 2023·2 cites·10 claims
- 0267US2023053305A1BCMA-Targeted Chimeric Antigen Receptor as well as Preparation Method Therefor and Application ThereofSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2022·Application pending·0 cites
- 0352US2024060041A1Methods for preparing tumor-infiltrating lymphocytesSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2021·Application pending·0 cites
- 0451US2024000839A1Bcma-targeted chimeric antigen receptorsSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2021·Application pending·0 cites
- 0549US2023181640A1Anti-bcma antibodies and chimeric antigen receptorsSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2021·Application pending·0 cites
- 0649US2023144447A1Cd22-targeted chimeric antigen receptor, preparation method therefor and application thereofSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2021·Application pending·0 cites
- 0746US2023407335A1Methods for Preparing Genetically Modified CellsSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →